Current Regulatory Status Overview FDA Classification In 2023, the FDA placed BPC-157 in Category 2 of substances presenting significant safety risks, explicitly prohibiting its use in compounded medications
PMID 8404634
GLP-1 analogues as adjunctive therapy for type 1 diabetes: systematic review and meta-analysis (24 RCTs, N=3,377)
Adults with type 2 diabetes should not take JARDIANCE if they have severe kidney problems or are on dialysis, or if they are allergic to empagliflozin or any ingredient in JARDIANCE
GHK-Cu is available in the following compounding formats: Topical direct skin application for dermatological benefits including collagen stimulation, wound healing, and pigmentation correction Hair foam scalp application to support hair growth and follicle health Hair dropper targeted scalp delivery for hair and follicle applications Troche sublingual dissolve for systemic absorption Frequently asked questions about GHK-Cu Q: Why does GHK-Cu need to be complexed with copper
The FDA will allow continued compounding of semaglutide until later this spring and announced that it will not take action against compounding pharmacies or distributors for tirzepatide until later this spring or when an injunction against the FDA is lifted
